Skip to main
MDAI

MDAI Stock Forecast & Price Target

MDAI Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Spectral AI is expected to experience significant growth in the coming years as it receives FDA clearance and begins its commercial launch of the DeepView System in the second half of 2026, with BARDA's support in distributing systems to burn centers and emergency departments in the US. The company's license model and focus on the underpenetrated and disjointed Advanced Wound Care market provide opportunities for recurring revenue and potential for Democratization of treatment. However, there are potential risks such as setbacks in regulatory or commercial approvals and lower uptake of the DeepView system in a commercial setting. The company's valuation and potential for revenue growth makes it a Buy with a PT of $4.00 based on a discounted sales analysis out to 2030.

Bears say

Spectral AI is a recent addition to the public market, with its DeepView system offering a potential solution for the under-penetrated and disjointed advanced wound care market. However, despite a recent BARDA contract and plans for international expansion, the company has yet to generate significant revenue and faces potential risks such as limited awareness of the technology and delays in regulatory and clinical timelines. Investors should approach this stock with caution and closely monitor its progress.

MDAI has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Spectral AI Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Spectral AI Inc (MDAI) Forecast

Analysts have given MDAI a Strong Buy based on their latest research and market trends.

According to 1 analysts, MDAI has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Spectral AI Inc (MDAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.